BusinessOcera Therapeutics Announces Late-Breaker Abstract Accepted for Presentation at the AASLD Liver Meeting 2016By Nasdaq OMXOct 24, 2016, 1:05 PM UTC
BusinessOcera Initiates Phase 1 Clinical Study of Orally Available OCR-002 in Patients with Cirrhosis for the Prevention of Hepatic EncephalopathyBy Nasdaq OMXSep 19, 2016, 1:05 PM UTC
BusinessGalectin Therapeutics to Present at Rodman & Renshaw 18th Annual Global Investment ConferenceBy Nasdaq OMXAug 31, 2016, 12:00 PM UTC
BusinessOcera Therapeutics Announces Presentation of Two Preclinical Studies Further Supporting Its Ammonia Scavenger OCR-002 at The International Liver Congress™ 2016 of the European Association for the Study of the Liver (EASL)By Nasdaq OMXApr 15, 2016, 1:05 PM UTC
BusinessOcera Therapeutics Announces Publication of Promising Preclinical Data in Support of Its Ammonia Scavenger OCR-002 in the Journal of HepatologyBy Nasdaq OMXApr 11, 2016, 1:05 PM UTC
BusinessOcera Therapeutics Reports Fourth Quarter and Full Year 2015 Financial Results and Provides Corporate UpdateBy Nasdaq OMXMar 3, 2016, 2:05 PM UTC
